Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride increased testosterone and estrogen, stopped hair loss, and promoted regrowth. Users discussed side effects like libido changes and considered adding minoxidil and aromatase inhibitors.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

The conversation discusses whether adding latanoprost to finasteride and minoxidil is more effective for hair loss than using finasteride and minoxidil alone. Users criticize the lack of comparison to the established combination of finasteride and minoxidil.

The user did not respond to minoxidil and is considering using tretinoin to improve results. They also explored finasteride, microneedling, adapalene, red light therapy, and oral minoxidil as potential treatments.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The user reported positive hair regrowth after 11 months on finasteride and 4 months of microneedling. Opinions in the conversation vary, with some endorsing microneedling as effective and others emphasizing finasteride as essential, while acknowledging that treatments may not work for everyone.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The user experienced severe side effects from finasteride, including hormonal imbalances and cognitive issues, leading to a recommendation to stop its use. They plan to follow up with tests to rule out a pituitary tumor and are considering topical treatments as alternatives.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

User reported initial hair regrowth with 0.25 mg finasteride taken four times a week, experiencing a second shedding phase, and no side effects. They also mentioned using RU58841 without success and plan to stop after a year.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation is about using a DHT-blocking supplement alongside finasteride for hair loss. The user decided against the supplement and increased their finasteride dose from 1 mg to 2.5 mg per day.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

A user experienced increased estradiol, nipple tenderness, and ED after taking finasteride. They are considering dose reduction to mitigate these effects.

Taking finasteride alone did not stop hair loss, but adding vitamin D3 and iron supplements improved hair coverage and quality. It's important to check and address deficiencies, but caution is advised with iron supplementation without medical guidance.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.

The positive effects of taking finasteride for hair loss, with the poster being four months into treatment and seeing improved thickness on their right side of scalp. Another user replied expressing hope in having similar results after starting to take finasteride.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user has been using 1 mg finasteride, topical minoxidil twice daily, 1 biotin vitamin, and a 0.5 mm dermaroller for hair loss treatment since April. They've seen progress but experienced a shedding event in October, and are hoping for increased density in the coming months.

The user is happy with their 2-month progress using a 3-in-1 oral tablet containing finasteride, minoxidil, and biotin, with minor side effects like slightly lower libido. They report no significant issues like breakouts and note that oral treatments are more effective than topical ones.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.